EFX
60
11
AAP
29
-3
NKE
37
-3
UNH
44
2
ZION
57
-3
ROK
52
-2
MAC
67
2
CSCO
61
-3
WU
28
-4
RL
75
3
GT
56
-2
WBA
64
4
MAR
62
-3
CMS
57
3
AIV
65
-6
CVX
23
-2
RSG
62
-2
EXPD
37
-2
KO
44
-2
EXR
48
-3
EFX
60
11
AAP
29
-3
NKE
37
-3
UNH
44
2
ZION
57
-3
ROK
52
-2
MAC
67
2
CSCO
61
-3
WU
28
-4
RL
75
3
GT
56
-2
WBA
64
4
MAR
62
-3
CMS
57
3
AIV
65
-6
CVX
23
-2
RSG
62
-2
EXPD
37
-2
KO
44
-2
EXR
48
-3
Financhill
Back

Xvivo Perfusion AB 10K Form

Buy
68

XVIPF
Xvivo Perfusion AB

Last Price:
42.90
Seasonality Move:
-0.87%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive XVIPF News And Ratings

See the #1 stock for the next 7 days that we like better than XVIPF

XVIPF Financial Statistics

Sales & Book Value

Annual Sales: $56.44M
Cash Flow: $2.27M
Price / Cash Flow: 205.72
Annual Sales: $6.56
Price / Book: 6.54

Profitability

EPS (TTM): 0.62690
Net Income (TTM): $19.46M
Gross Margin: $42.04M
Return on Equity: 10.19%
Return on Assets: 9.06%

Xvivo Perfusion AB Earnings Forecast

Key Xvivo Perfusion AB Financial Ratios

  • The Gross Profit Margin over the past 11 years for XVIPF is 74.49%.
  • The Selling, General & Administrative Expenses for XVIPF have been equal to 51.75% of Gross Profit Margin.
  • The Research & Development expenses have been 22.75% of Revenue.
  • The Interest Expense is 1.30% of Operating Income.
  • The Net Earning history of XVIPF is 15.37% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Xvivo Perfusion AB Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: XVIPF
Website: xvivoperfusion.com

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 5.49
Quick Ratio: 4.23

Price-to-Earnings

Trailing P/E Ratio: 147.95
Forward P/E Ratio: 0

XVIPF Technical Analysis vs Fundamental Analysis

Buy
68
Xvivo Perfusion AB (XVIPF) is a Buy

Is Xvivo Perfusion AB a Buy or a Sell?